CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −3,500 | 161,492 | ||
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +8,541 | $12.50 | $107K | 22,760 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +1,458 | $34.39 | $50K | 24,218 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −5,741 | $80.03 | $459K | 18,477 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −2,100 | $80.76 | $170K | 16,377 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −1,958 | $81.86 | $160K | 14,419 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −200 | $82.84 | $17K | 14,219 |
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −8,541 | 76,376 | ||
| 2026-10-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,458 | 56,875 | ||
| 2026-10-01 | Klein Lawrence Otto Chief Executive Officer | Option exercise 10b5-1 | +25,000 | $7.80 | $195K | 948,128 |
| 2026-10-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −16,246 | $83.40 | $1.4M | 931,882 |
| 2026-10-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −8,554 | $84.03 | $719K | 923,328 |
| 2026-10-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −200 | $84.78 | $17K | 923,128 |
| 2026-10-01 | Klein Lawrence Otto Chief Executive Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −25,000 | 1,528,513 | ||
| 2026-09-21 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −533 | $95.75 | $51K | 14,219 |
| 2026-09-21 | Quinlan Paul T General Counsel | Option exercise 10b5-1 | +10,000 | $7.80 | $78K | 39,995 |
| 2026-09-21 | Quinlan Paul T General Counsel | Sale 10b5-1 | −2,900 | $92.37 | $268K | 37,095 |
| 2026-09-21 | Quinlan Paul T General Counsel | Sale 10b5-1 | −3,832 | $93.32 | $358K | 33,263 |
| 2026-09-21 | Quinlan Paul T General Counsel | Sale 10b5-1 | −601 | $94.44 | $57K | 32,662 |
| 2026-09-21 | Quinlan Paul T General Counsel | Sale 10b5-1 | −2,667 | $95.31 | $254K | 29,995 |
Page 3 of 18 · 346 trades